Tirzepatide is the approved dual agonist that redefined expectations for weight-loss drugs; retatrutide is the investigational "triple G" agonist many believe could go further still. The key distinction is how many hormone systems each engages: tirzepatide hits two receptors (GIP and GLP-1), while retatrutide adds a third — the glucagon receptor, which may raise energy expenditure on top of appetite suppression. The crucial caveat is maturity: tirzepatide is FDA-approved with completed phase 3 trials, whereas retatrutide's striking early numbers come from earlier-stage studies.
At a glance
| Tirzepatide | Retatrutide | |
|---|---|---|
| Drug class | Dual GIP + GLP-1 agonist | Triple GIP + GLP-1 + glucagon agonist |
| Brand names | Mounjaro, Zepbound | None (investigational) |
| FDA status | Approved | Investigational — not approved |
| Reported trial weight loss | ~20–22% (phase 3) | ~24% at 48 weeks (phase 2) |
| Added mechanism | GIP on top of GLP-1 | Glucagon agonism (energy expenditure) on top of GIP/GLP-1 |
| Dosing | Once weekly injection | Once weekly injection (in trials) |
| Evidence maturity | Completed phase 3; large data set | Earlier-stage; long-term data still emerging |
The bottom line
Bottom line: Retatrutide's phase 2 weight-loss numbers are the highest reported for this drug class, and its glucagon activity is a genuinely different mechanism. But tirzepatide is a finished, approved product with a far larger safety and efficacy record, while retatrutide is still investigational and cannot be lawfully prescribed for weight loss. More-impressive early numbers are not the same as a proven, available medicine.
Frequently asked questions
Is retatrutide stronger than tirzepatide?
In early-stage trials retatrutide produced the largest average weight loss reported in this drug class (~24% at 48 weeks), edging out tirzepatide's ~20–22%. However, retatrutide is investigational and its data are less mature, so direct conclusions are premature.
What makes retatrutide a 'triple agonist'?
Retatrutide activates three receptors — GIP, GLP-1 and glucagon — whereas tirzepatide activates only GIP and GLP-1. The glucagon component may increase energy expenditure in addition to reducing appetite.
Is retatrutide FDA-approved?
No. Retatrutide is an investigational compound in clinical development and is not FDA-approved. Tirzepatide is approved and available by prescription. 'Retatrutide' sold outside trials is an unregulated research chemical.
References
Combined peer-reviewed sources from both peptide guides. Inclusion is not endorsement.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. Peer-reviewed study
- Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med. 2021. Peer-reviewed study
- Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025. Peer-reviewed study
- Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023. Peer-reviewed study
- Zhao L, Cheng Z, Lu Y, et al. Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial. JAMA. 2024. Peer-reviewed study
- Loomba R, Hartman ML, Lawitz EJ, et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024. Peer-reviewed study
- Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023. Peer-reviewed study
- Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP/GLP-1/glucagon receptor agonist, in people with type 2 diabetes: a randomised phase 2 trial. Lancet. 2023. Peer-reviewed study
- Katsi V, Koutsopoulos G, Fragoulis C, et al. Retatrutide-A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025. Peer-reviewed study
- Abdul-Rahman T, Roy P, Ahmed FK, et al. The power of three: Retatrutide's role in modern obesity and diabetes therapy. Eur J Pharmacol. 2024. Peer-reviewed study
- Giblin K, Kaplan LM, Somers VK, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab. 2026. Peer-reviewed study
- Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024. Peer-reviewed study